152 related articles for article (PubMed ID: 7584486)
21. Prophylaxis of graft-versus-host disease in identical sibling donor bone marrow transplant by anti-IL-2 receptor monoclonal antibody LO-Tact-1.
Ferrant A; Latinne D; Bazin H; Straetmans N; Cornet A; de la Parra B; Michaux JL
Bone Marrow Transplant; 1995 Oct; 16(4):577-81. PubMed ID: 8528175
[TBL] [Abstract][Full Text] [Related]
22. Treatment of steroid-resistant acute graft-vs-host disease by in vivo administration of an anti-T-cell ricin A chain immunotoxin.
Kernan NA; Byers V; Scannon PJ; Mischak RP; Brochstein J; Flomenberg N; Dupont B; O'Reilly RJ
JAMA; 1988 Jun; 259(21):3154-7. PubMed ID: 3285046
[TBL] [Abstract][Full Text] [Related]
23. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation.
Solomon SR; Nakamura R; Read EJ; Leitman SF; Carter C; Childs R; Dunbar CE; Young NS; Barrett AJ
Bone Marrow Transplant; 2003 May; 31(9):783-8. PubMed ID: 12732885
[TBL] [Abstract][Full Text] [Related]
24. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.
Filipovich AH; Vallera D; McGlave P; Polich D; Gajl-Peczalska K; Haake R; Lasky L; Blazar B; Ramsay NK; Kersey J
Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319
[TBL] [Abstract][Full Text] [Related]
25. Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience.
Micallef IN; Chhanabhai M; Gascoyne RD; Shepherd JD; Fung HC; Nantel SH; Toze CL; Klingemann HG; Sutherland HJ; Hogge DE; Nevill TJ; Le A; Barnett MJ
Bone Marrow Transplant; 1998 Nov; 22(10):981-7. PubMed ID: 9849695
[TBL] [Abstract][Full Text] [Related]
26. Differences between lymphocyte subsets, after allogeneic bone marrow transplantation, in patients who received tacrolimus and patients who received cyclosporin A.
Fukuda H; Teshima H; Karasuno T; Hiraoka A; Nakamura H; Masaoka T
Int J Hematol; 2000 Jan; 71(1):70-4. PubMed ID: 10729997
[TBL] [Abstract][Full Text] [Related]
27. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
[TBL] [Abstract][Full Text] [Related]
28. Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Lee CK; deMagalhaes-Silverman M; Hohl RJ; Hayashi M; Buatti J; Wen BC; Schlueter A; Strauss RG; Gingrich RD
Bone Marrow Transplant; 2003 Jan; 31(2):121-8. PubMed ID: 12621494
[TBL] [Abstract][Full Text] [Related]
29. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
30. Muromonab-CD3 (Orthoclone OKT3), methylprednisolone and cyclosporine for acute graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation.
Benekli M; Hahn T; Williams BT; Cooper M; Roy HN; Wallace P; Stewart C; Bambach B; McCarthy PL
Bone Marrow Transplant; 2006 Sep; 38(5):365-70. PubMed ID: 16862164
[TBL] [Abstract][Full Text] [Related]
31. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
Grossbard ML; Multani PS; Freedman AS; O'Day S; Gribben JG; Rhuda C; Neuberg D; Nadler LM
Clin Cancer Res; 1999 Sep; 5(9):2392-8. PubMed ID: 10499609
[TBL] [Abstract][Full Text] [Related]
32. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect.
Barrett AJ; Mavroudis D; Tisdale J; Molldrem J; Clave E; Dunbar C; Cottler-Fox M; Phang S; Carter C; Okunnieff P; Young NS; Read EJ
Bone Marrow Transplant; 1998 Mar; 21(6):543-51. PubMed ID: 9543057
[TBL] [Abstract][Full Text] [Related]
33. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
34. [Clinical study of a new protocol for acute graft-versus host disease prophylaxis in HLA-haploidentical bone marrow transplantation (BMT)].
Ji SQ; Chen HR; Wang HX; Yan HM; Liu J; Xue M; Zhu L
Zhonghua Xue Ye Xue Za Zhi; 2003 Aug; 24(8):416-9. PubMed ID: 14642179
[TBL] [Abstract][Full Text] [Related]
35. The impact of partial T cell depletion on overall transplant-related toxicity, graft function and survival after HLA-identical allogeneic bone marrow transplantation in standard risk adult patients with leukemia.
Schots R; Van Riet I; Ben Othman T; Trullemans F; De Waele M; Van Camp B
Bone Marrow Transplant; 2001 Nov; 28(10):917-22. PubMed ID: 11753544
[TBL] [Abstract][Full Text] [Related]
36. Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
Jansen J; Hanks S; Akard L; Martin M; Thompson J; Chang Q; Ash R; Garrett P; Figg F; English D
Bone Marrow Transplant; 1995 Feb; 15(2):271-8. PubMed ID: 7773217
[TBL] [Abstract][Full Text] [Related]
37. Ex vivo depletion of human bone marrow T lymphocytes by soybean lectin fractionation followed by treatment with an anti-pan-T cell (CD5) ricin A- chain immunotoxin.
Siena S; Villa S; Bonadonna G; Bregni M; Gianni AM
Transplant Proc; 1987 Feb; 19(1 Pt 3):2735-7. PubMed ID: 3274583
[No Abstract] [Full Text] [Related]
38. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
39. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease.
Byers VS; Henslee PJ; Kernan NA; Blazar BR; Gingrich R; Phillips GL; LeMaistre CF; Gilliland G; Antin JH; Martin P
Blood; 1990 Apr; 75(7):1426-32. PubMed ID: 2180494
[TBL] [Abstract][Full Text] [Related]
40. Hematopoietic growth factors after HLA-identical allogeneic bone marrow transplantation in patients treated with methotrexate-containing graft-vs.-host disease prophylaxis.
Martin-Algarra S; Bishop MR; Tarantolo S; Cowles MK; Reed E; Anderson JR; Vose JM; Bierman P; Armitage JO; Kessinger A
Exp Hematol; 1995 Dec; 23(14):1503-8. PubMed ID: 8542938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]